Novel treatment has 97 percent success rate in co-infected patients —
Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV. … Read the full story from the UC San Diego News Center
David L. Wyles, MD, is lead author of the New England Journal of Medicine article that reports the results of the multi-center study. Dr. Wyles is associate professor of clinical medicine in the Division of Infectious Diseases.
Read the article online:
Wyles D.L., Ruane P.J., Sulkowski M.S., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal of Medicine July 21, 2015, 10.1056/NEJMoa1503153. Free full text